ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 94 filers reported holding ARBUTUS BIOPHARMA CORP in Q1 2021. The put-call ratio across all filers is 2.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $357,562 | -15.9% | 176,139 | -4.7% | 0.00% | – |
Q2 2023 | $425,282 | -62.4% | 184,905 | -50.5% | 0.00% | – |
Q1 2023 | $1,131,506 | +162.2% | 373,434 | +101.6% | 0.00% | – |
Q4 2022 | $431,535 | +20.9% | 185,208 | -0.8% | 0.00% | – |
Q3 2022 | $357,000 | -19.4% | 186,776 | +14.4% | 0.00% | – |
Q2 2022 | $443,000 | -9.4% | 163,307 | -0.5% | 0.00% | – |
Q1 2022 | $489,000 | – | 164,130 | +16412900.0% | 0.00% | – |
Q2 2021 | $0 | -100.0% | 1 | -99.7% | 0.00% | – |
Q1 2021 | $1,000 | -99.2% | 300 | -98.4% | 0.00% | – |
Q3 2017 | $119,000 | +72.5% | 19,200 | 0.0% | 0.00% | – |
Q2 2017 | $69,000 | +11.3% | 19,200 | 0.0% | 0.00% | – |
Q1 2017 | $62,000 | +31.9% | 19,200 | 0.0% | 0.00% | – |
Q4 2016 | $47,000 | -28.8% | 19,200 | 0.0% | 0.00% | – |
Q3 2016 | $66,000 | -1.5% | 19,200 | 0.0% | 0.00% | – |
Q2 2016 | $67,000 | -15.2% | 19,200 | 0.0% | 0.00% | – |
Q1 2016 | $79,000 | -7.1% | 19,200 | 0.0% | 0.00% | – |
Q4 2015 | $85,000 | +19.7% | 19,200 | +65.5% | 0.00% | – |
Q3 2015 | $71,000 | – | 11,600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JACOB ASSET MANAGEMENT OF NEW YORK LLC | 260,000 | $866,000 | 0.34% |
RTW INVESTMENTS, LP | 5,978,355 | $19,908,000 | 0.31% |
GSA CAPITAL PARTNERS LLP | 309,839 | $1,032,000 | 0.17% |
QCM Cayman, Ltd. | 12,728 | $42,000 | 0.13% |
COWEN AND COMPANY, LLC | 486,717 | $1,621,000 | 0.11% |
Hudson Bay Capital Management LP | 1,400,000 | $4,662,000 | 0.06% |
Kerrisdale Advisers, LLC | 208,150 | $693,000 | 0.05% |
Secure Asset Management, LLC | 10,000 | $33,000 | 0.02% |
PDT Partners, LLC | 72,500 | $241,000 | 0.02% |
Point72 Asset Management, L.P. | 1,037,700 | $3,456,000 | 0.02% |